EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial

Jiaming Sun, Lei Wang, Yan Wu, Shannon Humphrey iD, Shyi-Gen Chen, William McGillivray iD, Shu-Hung Huang iD, Yuguang Zhang, Grace Pan, Catherine Foley iD, Elisabeth Lee, Joan-En Chang-Lin und 4 weitere

Aesthetic Surgery Journal · 2025

DOI: 10.1093/asj/sjaf204 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Aesthetic Surgery Journal, 2025. Verfasst von Jiaming Sun und 15 weiteren Autor:innen. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Masseter Muscle, Neuromuscular Agents. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergan Aesthetics, an AbbVie company, Shenavia Balcom-Luker, AbbVie Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Masseter muscle prominence (MMP) may be aesthetically bothersome to some individuals, leading them to seek treatment for a slimmer lower face.

Objectives

The aim of this study was to evaluate the safety and efficacy of onabotulinumtoxinA for the treatment of MMP, including patient-reported outcomes (PROs).

Methods

This was a prospective, multicenter trial including a randomized, double-blind, placebo-controlled period (Days 1−180) in which adults rated Grade 4 or 5 (marked/very marked) on the investigator-assessed MMP Scale (MMPS) were randomized to onabotulinumtoxinA 72 U or placebo. Efficacy endpoints were assessed at Day 90. The primary endpoint was ≥2-grade improvement from baseline on the investigator-assessed MMPS. Secondary endpoints included achieving Grade ≤3 on the MMPS and participant-assessed MMPS—Participant (MMPS-P), ≥2-grade improvement on the participant-assessed MMPS-P, and change from baseline in lower-facial width. Outcomes were assessed using validated measures. Adverse events (AEs) were monitored.

Results

Of 376 enrolled participants (onabotulinumtoxinA, n = 283; placebo, n = 93), 310 (82.4%) completed the study. At Day 90, a greater proportion of onabotulinumtoxinA-treated participants vs placebo achieved MMPS ≥2-grade improvement (51.2% vs 2.2%, P < .0001), and more onabotulinumtoxinA-treated participants vs placebo achieved the secondary endpoints (all P < .0001), with a mean lower-facial width reduction of −5.24 mm for onabotulinumtoxinA vs −0.04 mm for placebo (P < .0001). Participants reported benefits for onabotulinumtoxinA vs placebo in self-perceived change in MMP, treatment satisfaction, and psychosocial impact. Improvements were sustained through Day 180. Most AEs were mild, nonserious, and resolved.

Conclusions

OnabotulinumtoxinA effectively reduced the appearance of MMP and improved PROs, with effects lasting up to 6 months and a favorable safety profile. Level of Evidence: 1 (Therapeutic)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AMasseter MuscleNeuromuscular AgentsHumansFemalePatient Reported Outcome MeasuresMaleMiddle AgedDouble-Blind MethodAdultTreatment OutcomeProspective StudiesInjections, IntramuscularAged

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

ORCID-Profile: Shannon Humphrey, William McGillivray, Shu-Hung Huang, Catherine Foley, Donna L Faletto

Förderung

  • Allergan Aesthetics, an AbbVie company
  • Shenavia Balcom-Luker
  • AbbVie Inc
  • LLC

Zitieren

APA

Sun, J., Wang, L., Wu, Y., Humphrey, S., Chen, S. G., McGillivray, W., Huang, S. H., Zhang, Y., Pan, G., Foley, C., Lee, E., Chang-Lin, J. E., Faletto, D. L., Patel, V., Bowen, B., & Brin, M. F. (2025). OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjaf204

Vancouver

Sun J, Wang L, Wu Y, Humphrey S, Chen SG, McGillivray W, et al. OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial. Aesthetic Surgery Journal. 2025. doi:10.1093/asj/sjaf204

BibTeX
@article{Sun2025,
  author = {Sun, Jiaming and Wang, Lei and Wu, Yan and Humphrey, Shannon and Chen, Shyi-Gen and McGillivray, William and Huang, Shu-Hung and Zhang, Yuguang and Pan, Grace and Foley, Catherine and Lee, Elisabeth and Chang-Lin, Joan-En and Faletto, Donna L and Patel, Vaishali and Bowen, Beta and Brin, Mitchell F},
  title = {OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial},
  journal = {Aesthetic Surgery Journal},
  year = {2025},
  doi = {10.1093/asj/sjaf204}
}
Kostenlos starten →